



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 7/06		A1	(11) International Publication Number: WO 89/ 07436 (43) International Publication Date: 24 August 1989 (24.08.89)
(21) International Application Number: PCT/US88/00403 (22) International Filing Date: 18 February 1988 (18.02.88) (71) Applicant (for all designated States except US): THE UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US). (72) Inventor; and (75) Inventor/Applicant (for US only) : PENA, Lorraine, E. [US/US]; 1804 Cambridge Drive, Kalamazoo, MI 49001 (US). (74) Agent: WELCH, Lawrence, T.; Patent Law Depart- ment, The Upjohn Company, Kalamazoo, MI 49001 (US). (81) Designated States: AT (European patent), AU, BE (Eu- ropean patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (Euro- pean patent), IT (European patent), JP, KR, LU (Eu- ropean patent), NL (European patent), NO,		SE (European patent), US. Published <i>With international search report.</i>	
(54) Title: MINOXIDIL GEL			
(57) Abstract The present invention provides a novel pharmaceutically acceptable gel containing minoxidil for topical applica- tion.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MD	Moldova	US	United States of America
FI	Finland				

-1-

DESCRIPTION

MINOXIDIL GEL

BACKGROUND OF THE INVENTION

The present invention relates to a novel composition of matter.
5 More particularly, the present invention relates to a topical gel for the administration of minoxidil. The chemical name for minoxidil is 2,4-diamino-6-piperidinylpyrimidine-3-oxide and is the active ingredient of Loniten® tablets which are marketed by The Upjohn Company for hypertension. See, Physician's Desk Reference, 38th
10 Edition, page 2033 (1984). The preparation and antihypertensive use of this compound is described in U.S. Patent 3,461,461. This compound is also useful when applied topically to grow hair as described and claimed in U.S. Patent 4,139,619.

INFORMATION DISCLOSURE

15 The prior known topical pharmaceutical compositions of minoxidil are disclosed in U.S. Patent 4,139,619. This patent describes topical compositions comprising minoxidil and a topical pharmaceutical carrier selected from the group consisting of ointments, lotions, pastes, jellies, sprays, and aerosols. In
20 addition, pharmacies in the U.S. have made and sold gels of topical minoxidil containing carbomer, propylene glycol, and rubbing alcohol. Similarly, the pharmacists' column "Compounder's Corner", printed in, e.g., "The Missouri Pharmacist", page 35, (January 1987) suggests the preparation of a minoxidil gel containing carbopol, ethanol, and
25 water. Neither of these latter formulations are believed to be pharmaceutically elegant.

SUMMARY OF THE INVENTION

The present invention particularly provides:

(1) a pharmaceutically acceptable gel composition comprising
30 the following components on a percent weight to weight basis (% w/w)

<u>Component</u>	<u>% weight to weight</u>
(a) water	q.s. 100
(b) carbomer	0.25-1.5
(c) minoxidil	0.001-3
35 (d) pharmaceutically acceptable glycol	0.01-30
(e) ethanol or isopropanol	20-40
(f) a water and alcohol	0.25-1.5

-2-

soluble amine

with the proviso that the ratio of minoxidil to the glycol is sufficient for a saturated solution of minoxidil;

(2) a process for preparing a minoxidil gel comprising

5 (a) preparing the 3 mixtures or parts, each part containing components in the specified ranges, calculated on the basis of the final gel composition, expressed as percent weight-to-weight:

	<u>Part I</u>	<u>% w/w</u>
10 (i)	water	q.s. 100
(ii)	carbomer	0.25-1.5

	<u>Part II</u>	<u>% w/w</u>
(iii)	minoxidil	0.001-3
15 (iv)	a pharmaceutically acceptable glycol	0.01-30
(v)	ethanol or isopropanol	12.9-30
(vi)	a water and alcohol	0.25-1.5

soluble amine;

20 wherein the ratio of the minoxidil to the propylene glycol is sufficient for a saturated solution of minoxidil;

	<u>Part III</u>	<u>% w/w</u>
(vii)	ethanol or isopropanol	27.1-15
(viii)	a water and alcohol	0-0.4

25 soluble amine;

(b) adding Part III to Part I and mixing; and subsequently,

(c) adding Part II to the mixture of Parts III and I and mixing until a uniform gel is obtained.

30 The present invention thus provides a novel, pharmaceutically elegant means to topically administer minoxidil.

Pharmaceutically acceptable gels of minoxidil have not been previously described in any reference of which the inventor is aware.

35 Gels are semisolid systems consisting of either suspensions made up of small inorganic particles or large organic molecules interpenetrated by a liquid.

Single-phase gels, as used herein, consist of organic macro-

molecules uniformly distributed throughout a liquid in such a manner that no apparent boundaries exist between the dispersed macromolecules and the liquid. Single-phase gels may be made from synthetic macromolecules (e.g., Carbomer) or from natural gums
5 (e.g. Tragacanth).

The instantly claimed gel is a single phase gel made from a class of synthetic macromolecules called carbomers. A carbomer is a synthetic, high molecular weight, cross linked polymer of acrylic acid. Preferred for use in the instant invention is Carbopol® 934P,
10 a pharmaceutical grade commercial product sold by B.F. Goodrich Company. Carbopol® 934P has an approximate molecular weight of 3×10^6 . Carbomers are well known to those of ordinary skill in the pharmaceutical art.

Attempts to form pharmaceutically elegant carbomer gels of
15 minoxidil by conventional means are hampered by three processing difficulties:

- (1) the poor solubility of minoxidil;
- (2) difficulties in obtaining effective and efficient carbomer dispersion and maintenance of polymer solution; and
- 20 (3) precipitation of a drug-carbomer complex.

Surprisingly and unexpectedly, the method of the instant invention produces a pharmaceutically acceptable gel containing minoxidil which is pharmaceutically elegant and avoids the three problems noted above.

25 Conventional carbomer gel formulations involve the sequential mixing of a solvent, a polymer, and a neutralizing agent. The drug is added before the neutralizing agent is added. This sequence is generally preferred in the preparation of gels.

However, minoxidil cannot be formulated into a carbomer gel by
30 such conventional means. Addition of the components in the conventional manner leads to the formation of a white precipitate which is believed to be a minoxidil-carbomer complex. Isolation and analysis of the precipitate indicates the presence of both carbomer and minoxidil.

35 By "pharmaceutically acceptable glycol" is meant glycol which is non-toxic, and does not irritate the skin at the concentrations of this invention. Suitable glycols include propylene glycol, 1,3-butylene glycol, propylene glycol 200 (PEG 200), polyethylene glycol

-4-

400 (PEG 400) hexylene glycol, and dipropylene glycol. Propylene glycol is preferred.

The process used to prepare the gel of the instant invention proceeds as follows:

5 Three components are prepared separately and are mixed as described below. Part I contains carbomer (described in National Formulary (NF)XV at p. 1216 (1980 ed) and commercially available as Carbopol®) and water (preferably purified). This part may be prepared directly from carbomer and water or from a previously
10 prepared dispersion. A second part is prepared containing minoxidil from greater than 0 to 5% on a weight-to-weight basis; propylene glycol and/or 1,3-butylene glycol (1,3-butane diol), and/or other suitable glycol in an amount approximately 10 times that of the minoxidil for propylene glycol or an equivalent saturated amount for
15 other glycols; an alcohol (ethanol or isopropanol) in the range of 12.9 to 30% and an amine which is both water and alcohol soluble, such as diisopropanolamine (DIPA), triisopropanolamine, trolamine (triethanolamine), monoethanolamine or a polyamine such as Quadrol. DIPA, ethanol, and propylene glycol are preferred. The amine should
20 be present in the mixture in the range from about 0.25 to about 1.5%. A third part is prepared containing the above-described alcohol in the range of 27.1 to 5%. A small amount of the amine may also be present in this third part, i.e., up to 0.4% on a weight-to-weight basis. However, it is preferred that no amine be present in
25 Part III. All percents are expressed on a weight-to-weight basis.

Part III is then mixed with Part I by conventional means. After a uniform mixture is obtained, Part II is then added. A planetary mixing action under vacuum is preferred.

Surprisingly and unexpectedly it has been found that this
30 sequence of addition produces a pharmaceutically elegant gel which is not obtainable by conventional means. If the components are added in the conventional manner a white precipitate forms. The key element is the mixture of the amine with the minoxidil in Part II. The process precipitation problem is thus avoided. The preparation of
35 Parts I and III provide for a processible carbomer dispersion and helps to maintain the polymer solution, thereby insuring acceptable gel viscosity and clarity.

In order to produce and maintain drug solubility in the

-5-

preparation of Part II, the ratio of drug to the propylene glycol must be on the order of approximately 1 to 10 or an equivalent saturated amount for other glycols. A minimum amount of alcohol, determined by total drug concentration, is also required. If the minoxidil is not added simultaneously with the diisopropanolamine (DIPA) or similar amine to the carbomer dispersion, a stringy white precipitate forms. Thus, the addition of the DIPA or similar amine to Part II effectively "masks" the minoxidil and carbopol in such a way that these otherwise incompatible ingredients can be combined without difficulty.

A gel prepared using this process rather than conventional means avoids the problem of poor minoxidil solubility, allows the combination of otherwise incompatible ingredients, and facilitates carbomer dispersion manufacture.

A maximum concentration of alcohol of approximately 40% is preferred for satisfactory gels. This amount of alcohol is preferred to maintain fluidity of the Part I dispersion, since at higher minoxidil concentrations which necessitate a higher glycol content, further reductions in the fluid volume of Part I would result in a non-uniform, "doughy" mass during processing. An alternate reason for limiting the formulation alcohol to 40% is that the gel viscosity is reduced and hazing is increased in response to the carbomer's reaction to an unfavorable, potentially unstable, solvent environment.

Suitable colorants, perfumes, or similar pharmaceutical excipients may be added to the gel to obtain pharmaceutical elegance.

Surprisingly and unexpectedly it has been found that the formulation parameters described herein produce a gel with clarity and acceptable viscosity.

Minoxidil is well known and may be prepared by known means, e.g., as disclosed in U.S. Patent 3,461,461, which is expressly incorporated by reference herein. The minoxidil gels of the instant invention may be used as described in U.S. Patent 4,139,619, which is also expressly incorporated by reference herein.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is seen more fully by the Examples given below.

Example 1 Preparation of minoxidil gels.

-6-

Pharmaceutically elegant 1, 2, and 3% minoxidil gels are prepared by mixing the below-described 3 part mixtures:

A. Topical minoxidil gel 1%

<u>Part I</u>		<u>% w/w</u>
5	Purified water USP	q.s. 100
	Carbopol® 934P	0.45
<u>Part II</u>		
	minoxidil	1.0
	propylene glycol USP	10
10	alcohol USP	13
	diisopropanolamine NF	0.45

Part III

	alcohol USP	27
--	-------------	----

B. Topical minoxidil gel 2%.

15	<u>Part I</u>	<u>% w/w</u>
	purified water USP	q.s. 100
	carbopol 934P	0.5
	<u>Part II</u>	
	propylene glycol USP	20
20	alcohol USP	13
	minoxidil	2
	diisopropanolamine NF	0.5

Part III

	alcohol USP	27
--	-------------	----

25 C. Topical minoxidil gel 3%.

	<u>Part I</u>	<u>% w/w</u>
	purified water USP	q.s. 100
	carbopol 934P	0.5
	<u>Part II</u>	
30	minoxidil	3.0
	propylene glycol U.S.P.	30
	alcohol USP	13
	diisopropanolamine NF	0.5

Part III

35	alcohol USP	27
----	-------------	----

In each of the above cases, the component parts are prepared separately. Part III is then mixed with Part I. When a uniform

-7-

mixture is obtained, Part II is then added using planetary mixing under vacuum until a uniform gel is obtained.

Example 2 Topical minoxidil light gel 2%.

82.5 kg of minoxidil gel were prepared as described above using the following quantities in each part:

<u>% w/w</u>		<u>Part I</u>	<u>Amount</u>
0.5%		Carbopol® 934P	412 g, 500 mg
		Purified Water USP	30 kg, 937 g, 500 mg
		<u>Part II</u>	
10	20%	Propylene Glycol USP	16 kg, 500 g
	(2%)	Minoxidil Milled	(1 kg, 650 g)*
	13%	Alcohol USP	10 kg, 725 g
	0.5%	Diisopropanolamine NF	412 g, 500 mg
		Alcohol USP q.s.	
15		ad if necessary to	
		account for evaporation	29 kg, 287 g, 500 mg
		<u>Part III</u>	
	27%	Alcohol USP	22 kg, 275 g
		Alcohol USP q.s. ad	82 kg, 500 g

20

* Calculated by assay.

Preparation 1 Aqueous Carbomer Dispersion

A 1.604% Carbomer dispersion was prepared by mixing the following ingredients:

	<u>Amount</u>
Purified water, USP	73 kg
Carbopol® 934P	1 kg, 203 gm
Purified water, USP q.s. ad	75 kg

Mixing was performed in a Nauta mixer under vacuum. An opaque, smooth dispersion resulted.

30

Example 3 Minoxidil Gel 2%

A 2% minoxidil gel was prepared by mixing the following 3 parts as described below:

<u>% w/w</u>		<u>Part I</u>	<u>Kg.</u>	<u>Gm.</u>
35		Purified water USP	6	320
	1.604	Carbopol dispersion (Prep. 1)	31	170
		<u>Part II</u>		
	20	Propylene glycol USP	20	-

-8-

13	Alcohol USP	13	-
2	Minoxidil milled Assay 99.4%	2	012
0.5	DIPA	-	500

Part III

5	27	Alcohol USP	27	-
		Alcohol USP qs ad	100	-

Parts I and III were mixed in a Nauta mixer under vacuum. When a uniform mixture was obtained, the Part II component was added, and mixing was continued under vacuum until a uniform gel was obtained.

10 The product had a pH of 8.04, and a viscosity of 7980 centipoise at a shear rate of 7.61 sec^{-1} .

CLAIMS

1. A pharmaceutically acceptable gel composition comprising the following components on a percent weight to weight basis (% w/w)

	<u>Component</u>	<u>% weight to weight</u>
5	(a) water	q.s. 100
	(b) carbomer	0.25-1.5
	(c) minoxidil	0.001-3
	(d) pharmaceutically acceptable glycol	0.01-30
10	(e) ethanol or isopropanol	20-40
	(f) a water and alcohol soluble amine	0.25-1.5

with the proviso that the ratio of minoxidil to the glycol is sufficient for a saturated solution of minoxidil.

15

2. A process for preparing a minoxidil gel comprising

(i) preparing the 3 mixtures or parts, each part containing components in the specified ranges, calculated on the basis of the final gel composition, expressed as percent weight-to-weight:

	<u>Part I</u>	<u>% w/w</u>
	(a) water	q.s. 100
	(b) carbomer	0.25-1.5
25	<u>Part II</u>	<u>% w/w</u>
	(c) minoxidil	0.001-3
	(d) a pharmaceutically acceptable glycol	0.01-30
	(e) ethanol or isopropanol	12.9-30
30	(f) a water and alcohol soluble amine;	0.25-1.5

wherein the ratio of the minoxidil to the propylene glycol is sufficient for a saturated solution of minoxidil;

	<u>Part III</u>	<u>% w/w</u>
35	(g) ethanol or isopropanol	27.1-15
	(h) a water and alcohol soluble amine;	0-0.4
	(ii) adding Part III to Part I and mixing; and	

-10-

subsequently,

(iii) adding Part II to the mixture of Parts III and I and mixing until a uniform gel is obtained.

5 3. A gel of claim 1, wherein the amine is diisopropanolamine (DIPA), the alcohol is ethanol, the water is purified, and the glycol is propylene glycol.

10 4. A gel of claim 3, wherein the amount of minoxidil is 1.0%, the amount of carbomer is 0.45%, the amount of propylene glycol is 10%, the amount of ethanol is 40%, and the amount of DIPA is 0.45%.

15 5. A gel of claim 3, wherein the amount of minoxidil is 2.0%, the amount of carbomer is 0.5%, the amount of propylene glycol is 20%, the amount of ethanol is 40%, and the amount of DIPA is 0.5%.

20 6. A gel of claim 3, wherein the amount of minoxidil is 3%, the amount of carbomer is 0.5%, the amount of propylene glycol is 30%, the amount of ethanol is 40%, and the amount of DIPA is 0.5%.

7. A process of claim 2, wherein the amine is diisopropanolamine (DIPA), the alcohol is ethanol, the water is purified, and the glycol is propylene glycol.

25 8. A process of claim 7, wherein the following 3 parts are mixed:

Part I

% w/w

purified water USP

q.s. 100

Carbopol® 934P

0.5

Part II

30 propylene glycol USP

20

alcohol USP

13

minoxidil

2

diisopropanolamine NF

0.5

Part III

35 alcohol USP

27.

9. A process of claim 2, wherein the following 3 parts are mixed:

Part I

% w/w

-11-

	Purified water USP	q.s. 100
	Carbopol® 934P	0.45
	<u>Part II</u>	
	minoxidil	1.0
5	propylene glycol USP	10
	alcohol USP	13
	diisopropanolamine NF	0.45
	<u>Part III</u>	
	alcohol USP	27.
10	10. A process of claim 2, wherein the following 3 parts are mixed:	
	<u>Part I</u>	<u>% w/v</u>
	purified water USP	q.s. 100
	Carbopol® 934P	0.5
15	<u>Part II</u>	
	minoxidil	3.0
	propylene glycol	30
	alcohol USP	13
	diisopropanolamine NF	0.5
20	<u>Part III</u>	
	alcohol USP	27.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 88/00403

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁴ : A 61 K 7/06																				
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-bottom: 1px solid black; padding: 5px;">Classification System </td> <td style="border-bottom: 1px solid black; padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px;">IPC⁴ </td> <td style="padding: 5px;">A 61 K</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁴	A 61 K														
Classification System	Classification Symbols																			
IPC ⁴	A 61 K																			
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black; padding: 5px;">Category ⁹</th> <th style="width: 70%; border-bottom: 1px solid black; padding: 5px;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; border-bottom: 1px solid black; padding: 5px;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">FR, A, 2602424 (L'OREAL) 12 February 1988, see claims 1,2,5,7,10,12-16; page 5, line 38 - page 6, line 28; page 8, lines 14-34; examples 1,3,6-15 --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-10</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">EP, A, 0188793 (RICHARDSON-VICKS) 30 July 1986, see the whole document --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-10</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">GB, A, 2023000 (KOWA CO.) 28 December 1979, see the whole document --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-10</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">EP, A, 0104037 (TAKEDA CHEMICAL INDUSTRIES) 28 March 1984, see page 2, line 12 - page 4, line 9; page 5, lines 4-11; examples 1,3; claims 1,6-10 --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-10</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">FR, A, 2590897 (KEMYOS BIOMEDICAL RESEARCH) 5 June 1987, see the whole document -----</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-10</td> </tr> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	Y	FR, A, 2602424 (L'OREAL) 12 February 1988, see claims 1,2,5,7,10,12-16; page 5, line 38 - page 6, line 28; page 8, lines 14-34; examples 1,3,6-15 --	1-10	Y	EP, A, 0188793 (RICHARDSON-VICKS) 30 July 1986, see the whole document --	1-10	Y	GB, A, 2023000 (KOWA CO.) 28 December 1979, see the whole document --	1-10	A	EP, A, 0104037 (TAKEDA CHEMICAL INDUSTRIES) 28 March 1984, see page 2, line 12 - page 4, line 9; page 5, lines 4-11; examples 1,3; claims 1,6-10 --	1-10	A	FR, A, 2590897 (KEMYOS BIOMEDICAL RESEARCH) 5 June 1987, see the whole document -----	1-10
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																		
Y	FR, A, 2602424 (L'OREAL) 12 February 1988, see claims 1,2,5,7,10,12-16; page 5, line 38 - page 6, line 28; page 8, lines 14-34; examples 1,3,6-15 --	1-10																		
Y	EP, A, 0188793 (RICHARDSON-VICKS) 30 July 1986, see the whole document --	1-10																		
Y	GB, A, 2023000 (KOWA CO.) 28 December 1979, see the whole document --	1-10																		
A	EP, A, 0104037 (TAKEDA CHEMICAL INDUSTRIES) 28 March 1984, see page 2, line 12 - page 4, line 9; page 5, lines 4-11; examples 1,3; claims 1,6-10 --	1-10																		
A	FR, A, 2590897 (KEMYOS BIOMEDICAL RESEARCH) 5 June 1987, see the whole document -----	1-10																		
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>																				
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of the Actual Completion of the International Search 29th September 1988</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of Mailing of this International Search Report 25 OCT. 1988</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">International Searching Authority EUROPEAN PATENT OFFICE</td> <td style="border-bottom: 1px solid black; padding: 5px;">Signature of Authorized Officer P.C.G. VAN DER PUTTEN</td> </tr> </table>			Date of the Actual Completion of the International Search 29th September 1988	Date of Mailing of this International Search Report 25 OCT. 1988	International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer P.C.G. VAN DER PUTTEN														
Date of the Actual Completion of the International Search 29th September 1988	Date of Mailing of this International Search Report 25 OCT. 1988																			
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer P.C.G. VAN DER PUTTEN																			

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 8800403

SA 21173

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 18/10/88
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A- 2602424	12-02-88	DE-A- 3726177	11-02-88
		AU-A- 7661987	11-02-88
		LU-A- 86547	02-03-88
		SE-A- 8703068	08-02-88
		JP-A- 63044512	25-02-88
		GB-A- 2194887	23-03-88
		NL-A- 8701853	01-03-88

EP-A- 0188793	30-07-86	AU-A- 5080985	26-06-86
		JP-A- 61180709	13-08-86

GB-A- 2023000	28-12-79	BE-A- 868348	16-10-78
		NL-A- 7806785	28-12-79
		FR-A, B 2429018	18-01-80
		US-A- 4309414	05-01-82
		US-A- 4525347	25-06-85
		DE-A, C 2827018	10-01-80

EP-A- 0104037	28-03-84	JP-A- 59048413	19-03-84
		US-A- 4500511	19-02-85

FR-A- 2590897	05-06-87	GB-A- 2183632	10-06-87
		DE-A- 3544267	19-06-87

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.